KR20160148715A - B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온 - Google Patents
B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온 Download PDFInfo
- Publication number
- KR20160148715A KR20160148715A KR1020167034686A KR20167034686A KR20160148715A KR 20160148715 A KR20160148715 A KR 20160148715A KR 1020167034686 A KR1020167034686 A KR 1020167034686A KR 20167034686 A KR20167034686 A KR 20167034686A KR 20160148715 A KR20160148715 A KR 20160148715A
- Authority
- KR
- South Korea
- Prior art keywords
- methoxy
- ethyl
- dihydrobenzo
- oxo
- quinolizine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000011282 treatment Methods 0.000 title claims description 13
- 208000002672 hepatitis B Diseases 0.000 title description 2
- 238000011321 prophylaxis Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 115
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 32
- -1 di-C 1-6 alkylamino Chemical group 0.000 claims description 222
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 55
- 229910052739 hydrogen Inorganic materials 0.000 claims description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 45
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 38
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 31
- 239000007821 HATU Substances 0.000 claims description 30
- BXWKHIIAMJBZMP-UHFFFAOYSA-N 4h-quinolizine-3-carboxamide Chemical compound C1=CC=CN2CC(C(=O)N)=CC=C21 BXWKHIIAMJBZMP-UHFFFAOYSA-N 0.000 claims description 28
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 19
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000001153 fluoro group Chemical group F* 0.000 claims description 15
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 13
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 125000002757 morpholinyl group Chemical group 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
- 125000003386 piperidinyl group Chemical group 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 9
- 150000003857 carboxamides Chemical class 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- CTAVYWUMTZFOFF-UHFFFAOYSA-N 6-ethyl-10-methoxy-3-(methoxymethyl)-9-(3-methoxypropoxy)-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound C(C)C1CC2=C(C3=CC(C(=CN13)COC)=O)C=C(C(=C2)OCCCOC)OC CTAVYWUMTZFOFF-UHFFFAOYSA-N 0.000 claims description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 5
- DGCWHOHVNONFSD-UHFFFAOYSA-N quinolizin-2-one Chemical compound C1=CC=CC2=CC(=O)C=CN21 DGCWHOHVNONFSD-UHFFFAOYSA-N 0.000 claims description 5
- KQRWNHQNWJAORD-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-6-ethyl-10-methoxy-9-(3-methoxypropoxy)-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound CN(C)CC1=CN2C(CC3=C(C2=CC1=O)C=C(C(=C3)OCCCOC)OC)CC KQRWNHQNWJAORD-UHFFFAOYSA-N 0.000 claims description 4
- GBLRKIJYJPRMPG-UHFFFAOYSA-N 6-ethyl-10-methoxy-N-methylsulfonyl-2-oxo-9-phenylmethoxy-6,7-dihydrobenzo[a]quinolizine-3-carboxamide Chemical compound C(C1=CC=CC=C1)OC1=CC2=C(C3=CC(C(=CN3C(C2)CC)C(=O)NS(=O)(=O)C)=O)C=C1OC GBLRKIJYJPRMPG-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims description 4
- LTCHJIOBMNJQHJ-UHFFFAOYSA-N 6-ethyl-10-methoxy-9-(3-methoxypropoxy)-3-(methylaminomethyl)-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound C(C)C1CC2=C(C3=CC(C(=CN13)CNC)=O)C=C(C(=C2)OCCCOC)OC LTCHJIOBMNJQHJ-UHFFFAOYSA-N 0.000 claims description 3
- QZFVBHAZENHGMD-UHFFFAOYSA-N 6-ethyl-10-methoxy-9-(3-methoxypropoxy)-3-(piperidin-1-ylmethyl)-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound C(C)C1CC2=C(C3=CC(C(=CN13)CN1CCCCC1)=O)C=C(C(=C2)OCCCOC)OC QZFVBHAZENHGMD-UHFFFAOYSA-N 0.000 claims description 3
- NEKMSUAEPJWNBY-UHFFFAOYSA-N N-benzyl-6-ethyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxamide Chemical compound C(C1=CC=CC=C1)NC(=O)C1=CN2C(CC3=C(C2=CC1=O)C=C(C(=C3)OCCCOC)OC)CC NEKMSUAEPJWNBY-UHFFFAOYSA-N 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- TUTILOAXEMJXSI-UHFFFAOYSA-N 6-ethyl-10-methoxy-2-oxo-9-phenylmethoxy-N-propyl-6,7-dihydrobenzo[a]quinolizine-3-carboxamide Chemical compound C(C1=CC=CC=C1)OC1=CC2=C(C3=CC(C(=CN3C(C2)CC)C(=O)NCCC)=O)C=C1OC TUTILOAXEMJXSI-UHFFFAOYSA-N 0.000 claims description 2
- WFRHSVBYVIILQQ-UHFFFAOYSA-N 6-ethyl-10-methoxy-9-(3-methoxypropoxy)-3-(morpholin-4-ylmethyl)-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound C(C)C1CC2=C(C3=CC(C(=CN13)CN1CCOCC1)=O)C=C(C(=C2)OCCCOC)OC WFRHSVBYVIILQQ-UHFFFAOYSA-N 0.000 claims description 2
- GXCZFHUFLBJDPH-UHFFFAOYSA-N 6-ethyl-10-methoxy-N-(2-methoxyethyl)-2-oxo-9-phenylmethoxy-6,7-dihydrobenzo[a]quinolizine-3-carboxamide Chemical compound C(C1=CC=CC=C1)OC1=CC2=C(C3=CC(C(=CN3C(C2)CC)C(=O)NCCOC)=O)C=C1OC GXCZFHUFLBJDPH-UHFFFAOYSA-N 0.000 claims description 2
- RPXMWNGPBSDKNC-UHFFFAOYSA-N 6-ethyl-10-methoxy-N-methyl-2-oxo-9-phenylmethoxy-6,7-dihydrobenzo[a]quinolizine-3-carboxamide Chemical compound C(C1=CC=CC=C1)OC1=CC2=C(C3=CC(C(=CN3C(C2)CC)C(=O)NC)=O)C=C1OC RPXMWNGPBSDKNC-UHFFFAOYSA-N 0.000 claims description 2
- GPXUVVKDUSARDT-UHFFFAOYSA-N 6-ethyl-3-(hydroxymethyl)-10-methoxy-9-(3-methoxypropoxy)-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound CCC1CC2=C(C=C(OC)C(OCCCOC)=C2)C2=CC(=O)C(CO)=CN12 GPXUVVKDUSARDT-UHFFFAOYSA-N 0.000 claims description 2
- BJACRYHCFSBEHC-UHFFFAOYSA-N 6-ethyl-N-(2-hydroxyethyl)-10-methoxy-2-oxo-9-phenylmethoxy-6,7-dihydrobenzo[a]quinolizine-3-carboxamide Chemical compound C(C1=CC=CC=C1)OC1=CC2=C(C3=CC(C(=CN3C(C2)CC)C(=O)NCCO)=O)C=C1OC BJACRYHCFSBEHC-UHFFFAOYSA-N 0.000 claims description 2
- RCBXYFZIDIIHRB-UHFFFAOYSA-N C1=CC=CN2CC=CC(C(=O)N)=C21 Chemical compound C1=CC=CN2CC=CC(C(=O)N)=C21 RCBXYFZIDIIHRB-UHFFFAOYSA-N 0.000 claims description 2
- LGAMUCNZDXWMTL-UHFFFAOYSA-N N-benzyl-6-ethyl-10-methoxy-2-oxo-9-phenylmethoxy-6,7-dihydrobenzo[a]quinolizine-3-carboxamide Chemical compound C(C1=CC=CC=C1)NC(=O)C1=CN2C(CC3=C(C2=CC1=O)C=C(C(=C3)OCC3=CC=CC=C3)OC)CC LGAMUCNZDXWMTL-UHFFFAOYSA-N 0.000 claims description 2
- XFPYSNULJZXIPG-UHFFFAOYSA-N N-butan-2-yl-6-ethyl-10-methoxy-2-oxo-9-phenylmethoxy-6,7-dihydrobenzo[a]quinolizine-3-carboxamide Chemical compound C(C1=CC=CC=C1)OC1=CC2=C(C3=CC(C(=CN3C(C2)CC)C(=O)NC(C)CC)=O)C=C1OC XFPYSNULJZXIPG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 230000024717 negative regulation of secretion Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 131
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 173
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 110
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 104
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 90
- 238000002360 preparation method Methods 0.000 description 89
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
- 239000012044 organic layer Substances 0.000 description 56
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 45
- 239000011734 sodium Substances 0.000 description 45
- 238000001819 mass spectrum Methods 0.000 description 44
- 238000002953 preparative HPLC Methods 0.000 description 41
- 241000700721 Hepatitis B virus Species 0.000 description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 239000012267 brine Substances 0.000 description 39
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 39
- 238000005259 measurement Methods 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- 235000019439 ethyl acetate Nutrition 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 238000005481 NMR spectroscopy Methods 0.000 description 30
- 239000003921 oil Substances 0.000 description 30
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 238000000746 purification Methods 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 27
- 239000007864 aqueous solution Substances 0.000 description 26
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 239000000460 chlorine Substances 0.000 description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- WMNLMOUEXUARFU-UHFFFAOYSA-N 6-ethyl-10-methoxy-2-oxo-9-phenylmethoxy-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid Chemical compound C(C1=CC=CC=C1)OC1=CC2=C(C3=CC(C(=CN3C(C2)CC)C(=O)O)=O)C=C1OC WMNLMOUEXUARFU-UHFFFAOYSA-N 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 239000007795 chemical reaction product Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 9
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 8
- ULRPISSMEBPJLN-UHFFFAOYSA-N 2h-tetrazol-5-amine Chemical compound NC1=NN=NN1 ULRPISSMEBPJLN-UHFFFAOYSA-N 0.000 description 8
- OHXDYQXPDSOYDZ-UHFFFAOYSA-N 4h-quinolizine-3-carboxylic acid Chemical compound C1=CC=CN2CC(C(=O)O)=CC=C21 OHXDYQXPDSOYDZ-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 0 CCC(C*(c(C1C2)c3)cc(OCc4ccccc4)c3OC)N1C=C(C(NO)=O)C2=O Chemical compound CCC(C*(c(C1C2)c3)cc(OCc4ccccc4)c3OC)N1C=C(C(NO)=O)C2=O 0.000 description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- NXMXETCTWNXSFG-UHFFFAOYSA-N 1-methoxypropan-2-amine Chemical compound COCC(C)N NXMXETCTWNXSFG-UHFFFAOYSA-N 0.000 description 5
- JFSCCLJKKCRXSS-UHFFFAOYSA-N 4-bromo-1-methoxy-2-(3-methoxypropoxy)benzene Chemical compound COCCCOC1=CC(Br)=CC=C1OC JFSCCLJKKCRXSS-UHFFFAOYSA-N 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- FLPWBPAEWBUYLL-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)butan-2-amine Chemical compound CCC(N)CC1=CC=C(OC)C(OC)=C1 FLPWBPAEWBUYLL-UHFFFAOYSA-N 0.000 description 4
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 4
- WUEHBGDAHQCWSZ-UHFFFAOYSA-N 7-methoxy-6-(3-methoxypropoxy)-3-propan-2-yl-3,4-dihydroisoquinoline Chemical compound COC1=C(C=C2CC(N=CC2=C1)C(C)C)OCCCOC WUEHBGDAHQCWSZ-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229910010082 LiAlH Inorganic materials 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- TVFDJKKASGODPV-UHFFFAOYSA-N ethyl 6-ethyl-9-hydroxy-10-methoxy-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylate Chemical compound C(C)C1CC2=C(C3=CC(C(=CN13)C(=O)OCC)=O)C=C(C(=C2)O)OC TVFDJKKASGODPV-UHFFFAOYSA-N 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- XKIJOSXYTRKNDO-UHFFFAOYSA-N 1-cyclobutyl-2-[4-methoxy-3-(3-methoxypropoxy)phenyl]ethanamine Chemical compound C1(CCC1)C(CC1=CC(=C(C=C1)OC)OCCCOC)N XKIJOSXYTRKNDO-UHFFFAOYSA-N 0.000 description 3
- YMUFEVDTEAXXQF-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-3-(2,2,2-trifluoroethyl)aziridine Chemical compound COC=1C=C(C=CC1OC)C1NC1CC(F)(F)F YMUFEVDTEAXXQF-UHFFFAOYSA-N 0.000 description 3
- VMNZCBKLHBEJCE-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-5-(trifluoromethyl)-1,2-oxazole Chemical compound COC=1C=C(C=CC1OC)C1=NOC(=C1)C(F)(F)F VMNZCBKLHBEJCE-UHFFFAOYSA-N 0.000 description 3
- IOAZXFBHUYZJEG-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-5-ol Chemical compound COC=1C=C(C=CC1OC)C1=NOC(C1)(O)C(F)(F)F IOAZXFBHUYZJEG-UHFFFAOYSA-N 0.000 description 3
- IBWTYWVRKRDLGX-UHFFFAOYSA-N 3-ethyl-6,7-dimethoxy-3,4-dihydroisoquinoline Chemical compound C(C)C1N=CC2=CC(=C(C=C2C1)OC)OC IBWTYWVRKRDLGX-UHFFFAOYSA-N 0.000 description 3
- VQENUYDUSGXPHX-UHFFFAOYSA-N 3-ethyl-7-methoxy-6-phenylmethoxy-3,4-dihydroisoquinoline Chemical compound C(C1=CC=CC=C1)OC=1C=C2CC(N=CC2=CC1OC)CC VQENUYDUSGXPHX-UHFFFAOYSA-N 0.000 description 3
- GZAXORCUMWRYRG-UHFFFAOYSA-N 3-tert-butyl-7-methoxy-6-(3-methoxypropoxy)-3,4-dihydroisoquinoline Chemical compound C(C)(C)(C)C1N=CC2=CC(=C(C=C2C1)OCCCOC)OC GZAXORCUMWRYRG-UHFFFAOYSA-N 0.000 description 3
- SNPIMAUJYSWYNQ-UHFFFAOYSA-N 4-bromo-1-chloro-2-(3-methoxypropoxy)benzene Chemical compound COCCCOC1=CC(Br)=CC=C1Cl SNPIMAUJYSWYNQ-UHFFFAOYSA-N 0.000 description 3
- VQVQZFHUXRSRBZ-UHFFFAOYSA-N 4-methoxy-3-phenylmethoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1OCC1=CC=CC=C1 VQVQZFHUXRSRBZ-UHFFFAOYSA-N 0.000 description 3
- CQSVLKKGEFDDQW-UHFFFAOYSA-N 7-chloro-6-(3-methoxypropoxy)-3-propan-2-yl-3,4-dihydroisoquinoline Chemical compound ClC1=C(C=C2CC(N=CC2=C1)C(C)C)OCCCOC CQSVLKKGEFDDQW-UHFFFAOYSA-N 0.000 description 3
- WQKLBQXHADQQIO-UHFFFAOYSA-N 8-chloro-6-(2-methoxyethoxy)-3-propan-2-yl-3,4-dihydroisoquinoline Chemical compound ClC=1C=C(C=C2CC(N=CC12)C(C)C)OCCOC WQKLBQXHADQQIO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- 108020004638 Circular DNA Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- UOLZFACGBCQQLD-UHFFFAOYSA-N N-[1-(3,4-dimethoxyphenyl)butan-2-yl]formamide Chemical compound COC=1C=C(C=CC1OC)CC(CC)NC=O UOLZFACGBCQQLD-UHFFFAOYSA-N 0.000 description 3
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 3
- FDWKSNUZWSVDPF-UHFFFAOYSA-N ethyl 6-ethyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylate Chemical compound C(C)OC(=O)C1=CN2C(CC3=C(C2=CC1=O)C=C(C(=C3)OCCCOC)OC)CC FDWKSNUZWSVDPF-UHFFFAOYSA-N 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 3
- JUNOWSHJELIDQP-UHFFFAOYSA-N morpholin-4-ium-3-carboxylate Chemical compound OC(=O)C1COCCN1 JUNOWSHJELIDQP-UHFFFAOYSA-N 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 2
- TZZJGIBRBTYUHX-NSHDSACASA-N (6S)-6-ethyl-9,10-dimethoxy-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid Chemical compound C(C)[C@H]1CC2=C(C3=CC(C(=CN13)C(=O)O)=O)C=C(C(=C2)OC)OC TZZJGIBRBTYUHX-NSHDSACASA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- NRBCNHBQBWHAJU-UHFFFAOYSA-N 1,2-dimethoxy-4-(2-nitrobut-1-enyl)benzene Chemical compound CCC([N+]([O-])=O)=CC1=CC=C(OC)C(OC)=C1 NRBCNHBQBWHAJU-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- GQXPMIWXLUQESK-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-4,4,4-trifluorobutan-2-amine Chemical compound COC=1C=C(C=CC1OC)CC(CC(F)(F)F)N GQXPMIWXLUQESK-UHFFFAOYSA-N 0.000 description 2
- GTVMRWYSDHAPGE-UHFFFAOYSA-N 1-(4-methoxy-3-phenylmethoxyphenyl)butan-2-amine Chemical compound CCC(N)CC1=CC=C(OC)C(OCC=2C=CC=CC=2)=C1 GTVMRWYSDHAPGE-UHFFFAOYSA-N 0.000 description 2
- PZYKJRVKGNPAPO-UHFFFAOYSA-N 1-[3-chloro-5-(2-methoxyethoxy)phenyl]-3-methylbutan-2-one Chemical compound ClC=1C=C(C=C(C1)OCCOC)CC(C(C)C)=O PZYKJRVKGNPAPO-UHFFFAOYSA-N 0.000 description 2
- AKOBSOUCNKTKLZ-UHFFFAOYSA-N 1-bromo-3-chloro-5-(2-methoxyethoxy)benzene Chemical compound COCCOC1=CC(Cl)=CC(Br)=C1 AKOBSOUCNKTKLZ-UHFFFAOYSA-N 0.000 description 2
- CEVMYGZHEJSOHZ-UHFFFAOYSA-N 1-bromo-3-methoxypropane Chemical compound COCCCBr CEVMYGZHEJSOHZ-UHFFFAOYSA-N 0.000 description 2
- UTWXADXIAOYZTF-UHFFFAOYSA-N 1-chloro-2-(3-methoxypropoxy)-4-(3-methylbutyl)benzene Chemical compound ClC1=C(C=C(C=C1)CCC(C)C)OCCCOC UTWXADXIAOYZTF-UHFFFAOYSA-N 0.000 description 2
- FTZVMRWFMDZUFZ-UHFFFAOYSA-N 1-cyclobutyl-2-[4-methoxy-3-(3-methoxypropoxy)phenyl]ethanone Chemical compound C1(CCC1)C(CC1=CC(=C(C=C1)OC)OCCCOC)=O FTZVMRWFMDZUFZ-UHFFFAOYSA-N 0.000 description 2
- JSZOAYXJRCEYSX-UHFFFAOYSA-N 1-nitropropane Chemical compound CCC[N+]([O-])=O JSZOAYXJRCEYSX-UHFFFAOYSA-N 0.000 description 2
- MHNNOHNHCKOSGL-UHFFFAOYSA-N 10-chloro-9-(3-methoxypropoxy)-6-propan-2-yl-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound ClC=1C(=CC2=C(C3=CC(C=CN3C(C2)C(C)C)=O)C=1)OCCCOC MHNNOHNHCKOSGL-UHFFFAOYSA-N 0.000 description 2
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- YBXRSEJRJWASHX-UHFFFAOYSA-N 3-cyclobutyl-7-methoxy-6-(3-methoxypropoxy)-3,4-dihydroisoquinoline Chemical compound C1(CCC1)C1N=CC2=CC(=C(C=C2C1)OCCCOC)OC YBXRSEJRJWASHX-UHFFFAOYSA-N 0.000 description 2
- OCWVLVPSKIODGY-UHFFFAOYSA-N 4-(3,3-dimethylbutyl)-1-methoxy-2-(3-methoxypropoxy)benzene Chemical compound COC1=C(C=C(C=C1)CCC(C)(C)C)OCCCOC OCWVLVPSKIODGY-UHFFFAOYSA-N 0.000 description 2
- CHKQUOLXOZEJMN-UHFFFAOYSA-N 6,7-dimethoxy-3-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline Chemical compound COC=1C=C2CC(N=CC2=CC1OC)CC(F)(F)F CHKQUOLXOZEJMN-UHFFFAOYSA-N 0.000 description 2
- AQGIQEWWSOXMFF-UHFFFAOYSA-N 6-ethyl-10-methoxy-9-(2-methylpropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid Chemical compound C(C)C1CC2=C(C3=CC(C(=CN13)C(=O)O)=O)C=C(C(=C2)OCC(C)C)OC AQGIQEWWSOXMFF-UHFFFAOYSA-N 0.000 description 2
- LCOBSEFDAWQAMH-UHFFFAOYSA-N 6-ethyl-10-methoxy-9-phenylmethoxy-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound C(C1=CC=CC=C1)OC1=CC2=C(C3=CC(C=CN3C(C2)CC)=O)C=C1OC LCOBSEFDAWQAMH-UHFFFAOYSA-N 0.000 description 2
- DNGHIYAQZWYNAY-UHFFFAOYSA-N 9-ethoxy-6-ethyl-10-methoxy-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid Chemical compound C(C)OC1=CC2=C(C3=CC(C(=CN3C(C2)CC)C(=O)O)=O)C=C1OC DNGHIYAQZWYNAY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- HDSHMCJKVCXLOZ-UHFFFAOYSA-N C(C)C1C(C=CN2C(CC3=C(C12)C=C(C(=C3)OCC1=CC=CC=C1)OC)CC)=O Chemical compound C(C)C1C(C=CN2C(CC3=C(C12)C=C(C(=C3)OCC1=CC=CC=C1)OC)CC)=O HDSHMCJKVCXLOZ-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MZDKVDOANPPDAH-UHFFFAOYSA-N N-[1-(3,4-dimethoxyphenyl)-4,4,4-trifluorobutan-2-yl]formamide Chemical compound COC=1C=C(C=CC1OC)CC(CC(F)(F)F)NC=O MZDKVDOANPPDAH-UHFFFAOYSA-N 0.000 description 2
- FCHVBDIKBIJHOU-UHFFFAOYSA-N N-[1-[4-methoxy-3-(3-methoxypropoxy)phenyl]-3-methylbutan-2-yl]formamide Chemical compound COC1=C(C=C(C=C1)CC(C(C)C)NC=O)OCCCOC FCHVBDIKBIJHOU-UHFFFAOYSA-N 0.000 description 2
- GJJSRFKLIDXHAF-UHFFFAOYSA-N N-[1-cyclobutyl-2-[4-methoxy-3-(3-methoxypropoxy)phenyl]ethyl]formamide Chemical compound C1(CCC1)C(CC1=CC(=C(C=C1)OC)OCCCOC)NC=O GJJSRFKLIDXHAF-UHFFFAOYSA-N 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710086987 X protein Proteins 0.000 description 2
- IQZLUWLMQNGTIW-UHFFFAOYSA-N acetoveratrone Chemical compound COC1=CC=C(C(C)=O)C=C1OC IQZLUWLMQNGTIW-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125890 compound Ia Drugs 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- FNASCUBBFNCFQO-SOFGYWHQSA-N ethyl (2e)-2-(ethoxymethylidene)-3-oxobutanoate Chemical compound CCO\C=C(/C(C)=O)C(=O)OCC FNASCUBBFNCFQO-SOFGYWHQSA-N 0.000 description 2
- HPIHRRNYDBUIJL-UHFFFAOYSA-N ethyl 11-chloro-9-(2-methoxyethoxy)-2-oxo-6-propan-2-yl-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate Chemical compound ClC1=CC(=CC2=C1C1CC(C(=CN1C(C2)C(C)C)C(=O)OCC)=O)OCCOC HPIHRRNYDBUIJL-UHFFFAOYSA-N 0.000 description 2
- LQSOVGAUOHMPLK-UHFFFAOYSA-N ethyl 2-(dimethylaminomethylidene)-3-oxobutanoate Chemical compound CCOC(=O)C(C(C)=O)=CN(C)C LQSOVGAUOHMPLK-UHFFFAOYSA-N 0.000 description 2
- SCGZLAJLBHZDPK-UHFFFAOYSA-N ethyl 6-ethyl-10-methoxy-2-oxo-9-phenylmethoxy-6,7-dihydrobenzo[a]quinolizine-3-carboxylate Chemical compound C(C1=CC=CC=C1)OC1=CC2=C(C3=CC(C(=CN3C(C2)CC)C(=O)OCC)=O)C=C1OC SCGZLAJLBHZDPK-UHFFFAOYSA-N 0.000 description 2
- OSBBKWSMHYMKSC-UHFFFAOYSA-N ethyl 6-tert-butyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate Chemical compound C(C)(C)(C)C1CC2=C(C3CC(C(=CN13)C(=O)OCC)=O)C=C(C(=C2)OCCCOC)OC OSBBKWSMHYMKSC-UHFFFAOYSA-N 0.000 description 2
- SPUBZXDEFYRVFU-UHFFFAOYSA-N ethyl 9-(cyclopropylmethoxy)-6-ethyl-10-methoxy-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylate Chemical compound C1(CC1)COC1=CC2=C(C3=CC(C(=CN3C(C2)CC)C(=O)OCC)=O)C=C1OC SPUBZXDEFYRVFU-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical compound COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 description 2
- VXGABWCSZZWXPC-UHFFFAOYSA-N methyl 2-(methylamino)acetate Chemical compound CNCC(=O)OC VXGABWCSZZWXPC-UHFFFAOYSA-N 0.000 description 2
- VVYXIRKYWOEDRA-UHFFFAOYSA-N methyl morpholine-3-carboxylate Chemical compound COC(=O)C1COCCN1 VVYXIRKYWOEDRA-UHFFFAOYSA-N 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 1
- TZZJGIBRBTYUHX-LLVKDONJSA-N (6R)-6-ethyl-9,10-dimethoxy-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid Chemical compound C(C)[C@@H]1CC2=C(C3=CC(C(=CN13)C(=O)O)=O)C=C(C(=C2)OC)OC TZZJGIBRBTYUHX-LLVKDONJSA-N 0.000 description 1
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- VFOTZDXAJIYCFE-UHFFFAOYSA-N 1,6-diethyl-9-hydroxy-10-methoxy-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound C(C)C=1C(C=CN2C(CC3=C(C=12)C=C(C(=C3)O)OC)CC)=O VFOTZDXAJIYCFE-UHFFFAOYSA-N 0.000 description 1
- QYQACDYPMNIAMN-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-4,4,4-trifluorobutane-1,3-dione Chemical compound COC1=CC=C(C(=O)CC(=O)C(F)(F)F)C=C1OC QYQACDYPMNIAMN-UHFFFAOYSA-N 0.000 description 1
- OCNOEKXBUTWONL-UHFFFAOYSA-N 1-(3-ethoxy-4-methoxyphenyl)butan-2-amine Chemical compound CCOC1=CC(CC(N)CC)=CC=C1OC OCNOEKXBUTWONL-UHFFFAOYSA-N 0.000 description 1
- KTSHQRLIEHXPAP-UHFFFAOYSA-N 1-(4-chloro-3-ethoxyphenyl)butan-2-amine Chemical compound ClC1=C(C=C(C=C1)CC(CC)N)OCC KTSHQRLIEHXPAP-UHFFFAOYSA-N 0.000 description 1
- LLJDJUJNUQIKCI-UHFFFAOYSA-N 1-[4-chloro-3-(3-methoxypropoxy)phenyl]-3-methylbutan-2-one Chemical compound ClC1=C(C=C(C=C1)CC(C(C)C)=O)OCCCOC LLJDJUJNUQIKCI-UHFFFAOYSA-N 0.000 description 1
- MBPNKIOIPXMGRZ-UHFFFAOYSA-N 1-[4-methoxy-3-(3-methoxypropoxy)phenyl]-3,3-dimethylbutan-2-one Chemical compound COC1=C(C=C(C=C1)CC(C(C)(C)C)=O)OCCCOC MBPNKIOIPXMGRZ-UHFFFAOYSA-N 0.000 description 1
- GHJNETCPUNPHDG-UHFFFAOYSA-N 1-[4-methoxy-3-(3-methoxypropoxy)phenyl]-3-methylbutan-2-one Chemical compound COCCCOC1=CC(CC(=O)C(C)C)=CC=C1OC GHJNETCPUNPHDG-UHFFFAOYSA-N 0.000 description 1
- XOAPTHBFHONTTN-UHFFFAOYSA-N 1-[4-methoxy-3-(3-methoxypropoxy)phenyl]ethanone Chemical compound COCCCOC1=CC(C(C)=O)=CC=C1OC XOAPTHBFHONTTN-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- JPJOOTWNILDNAW-UHFFFAOYSA-N 1-cyclobutylethanone Chemical compound CC(=O)C1CCC1 JPJOOTWNILDNAW-UHFFFAOYSA-N 0.000 description 1
- KBANDCMMDIOXJT-UHFFFAOYSA-N 1-methoxy-2-(3-methoxypropoxy)-4-(3-methylbutyl)benzene Chemical compound COC1=C(C=C(C=C1)CCC(C)C)OCCCOC KBANDCMMDIOXJT-UHFFFAOYSA-N 0.000 description 1
- KHPOTAFHGQKBSZ-UHFFFAOYSA-N 1-methoxy-4-(2-nitrobut-1-enyl)-2-phenylmethoxybenzene Chemical compound CCC([N+]([O-])=O)=CC1=CC=C(OC)C(OCC=2C=CC=CC=2)=C1 KHPOTAFHGQKBSZ-UHFFFAOYSA-N 0.000 description 1
- RRQHLOZQFPWDCA-UHFFFAOYSA-N 1-n,1-n-dimethylpropane-1,2-diamine Chemical compound CC(N)CN(C)C RRQHLOZQFPWDCA-UHFFFAOYSA-N 0.000 description 1
- KBXLMOYQNDMHQT-UHFFFAOYSA-N 10-methoxy-9-(3-methoxypropoxy)-2-oxo-6-propan-2-yl-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid Chemical compound C(C)(C)C1CC2=C(C3=CC(C(=CN13)C(=O)O)=O)C=C(C(=C2)OCCCOC)OC KBXLMOYQNDMHQT-UHFFFAOYSA-N 0.000 description 1
- PAGHTBBFXSFCBF-UHFFFAOYSA-N 11-chloro-9-(2-methoxyethoxy)-2-oxo-6-propan-2-yl-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid Chemical compound ClC1=CC(=CC2=C1C1=CC(C(=CN1C(C2)C(C)C)C(=O)O)=O)OCCOC PAGHTBBFXSFCBF-UHFFFAOYSA-N 0.000 description 1
- JJJXIUNGGWBGCR-UHFFFAOYSA-N 2-(dimethylaminomethylidene)-3-oxobutanoic acid Chemical compound CN(C)C=C(C(C)=O)C(O)=O JJJXIUNGGWBGCR-UHFFFAOYSA-N 0.000 description 1
- BKMMTJMQCTUHRP-UHFFFAOYSA-N 2-aminopropan-1-ol Chemical compound CC(N)CO BKMMTJMQCTUHRP-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GMGWXLPFRHYWAS-UHFFFAOYSA-N 3-bromo-5-chlorophenol Chemical compound OC1=CC(Cl)=CC(Br)=C1 GMGWXLPFRHYWAS-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- UEVFFMZHGNYDKM-UHFFFAOYSA-N 5-bromo-2-chlorophenol Chemical compound OC1=CC(Br)=CC=C1Cl UEVFFMZHGNYDKM-UHFFFAOYSA-N 0.000 description 1
- OLSJHVZRUFFIPL-UHFFFAOYSA-N 5-bromo-2-methoxyphenol Chemical compound COC1=CC=C(Br)C=C1O OLSJHVZRUFFIPL-UHFFFAOYSA-N 0.000 description 1
- WSXRLMQVRYGPDG-UHFFFAOYSA-N 6-ethyl-10-methoxy-9-(2-methylpropoxy)-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound C(C)C1CC2=C(C3=CC(C=CN13)=O)C=C(C(=C2)OCC(C)C)OC WSXRLMQVRYGPDG-UHFFFAOYSA-N 0.000 description 1
- SVDSDRPLKVITHW-UHFFFAOYSA-N 6-ethyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid Chemical compound C(C)C1CC2=C(C3=CC(C(=CN13)C(=O)O)=O)C=C(C(=C2)OCCCOC)OC SVDSDRPLKVITHW-UHFFFAOYSA-N 0.000 description 1
- KVKCNQRQHOJYSD-UHFFFAOYSA-N 6-ethyl-10-methoxy-9-(3-methoxypropoxy)-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound C(C)C1CC2=C(C3=CC(C=CN13)=O)C=C(C(=C2)OCCCOC)OC KVKCNQRQHOJYSD-UHFFFAOYSA-N 0.000 description 1
- NQJSHHZYEJHELF-UHFFFAOYSA-N 6-ethyl-9,10-dimethoxy-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound C(C)C1CC2=C(C3=CC(C=CN13)=O)C=C(C(=C2)OC)OC NQJSHHZYEJHELF-UHFFFAOYSA-N 0.000 description 1
- MFFBCFKMDSBJKI-UHFFFAOYSA-N 6-tert-butyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid Chemical compound C(C)(C)(C)C1CC2=C(C3=CC(C(=CN13)C(=O)O)=O)C=C(C(=C2)OCCCOC)OC MFFBCFKMDSBJKI-UHFFFAOYSA-N 0.000 description 1
- HMDMBQDTGROEJQ-UHFFFAOYSA-N 6H-benzo[a]quinolizine-3-carboxylic acid Chemical compound C1=CC(=CN2CC=C3C(=C12)C=CC=C3)C(=O)O HMDMBQDTGROEJQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- UDKGUTIBDQGIHS-UHFFFAOYSA-N 9,10-dimethoxy-6-(2,2,2-trifluoroethyl)-6,7-dihydrobenzo[a]quinolizin-2-one Chemical compound COC1=CC2=C(C3=CC(C=CN3C(C2)CC(F)(F)F)=O)C=C1OC UDKGUTIBDQGIHS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- SNTFRXSYDVAJKA-UHFFFAOYSA-N C(C)C=1C(C=CN2C(CC3=C(C=12)C=C(C(=C3)OCC1CC1)OC)CC)=O Chemical compound C(C)C=1C(C=CN2C(CC3=C(C=12)C=C(C(=C3)OCC1CC1)OC)CC)=O SNTFRXSYDVAJKA-UHFFFAOYSA-N 0.000 description 1
- XHXKXKCSUGSOAJ-UHFFFAOYSA-N C(C)C=1C(C=CN2C(CC3=C(C=12)C=C(C(=C3)OCCCOC)Cl)C(C)C)=O Chemical compound C(C)C=1C(C=CN2C(CC3=C(C=12)C=C(C(=C3)OCCCOC)Cl)C(C)C)=O XHXKXKCSUGSOAJ-UHFFFAOYSA-N 0.000 description 1
- XIPOYANJEHMQBS-UHFFFAOYSA-N C(C)C=1C(C=CN2C(CC3=C(C=12)C=C(C(=C3)OCCCOC)OC)C(C)C)=O Chemical compound C(C)C=1C(C=CN2C(CC3=C(C=12)C=C(C(=C3)OCCCOC)OC)C(C)C)=O XIPOYANJEHMQBS-UHFFFAOYSA-N 0.000 description 1
- YIKJAJWRQVEDMA-UHFFFAOYSA-N C(C)OC1=CC2=C(C3=CC=C(CN3C(C2=O)CC)C(=O)O)C=C1OC Chemical compound C(C)OC1=CC2=C(C3=CC=C(CN3C(C2=O)CC)C(=O)O)C=C1OC YIKJAJWRQVEDMA-UHFFFAOYSA-N 0.000 description 1
- BUQIAVHVUVAIHJ-UHFFFAOYSA-N C1=CC(=CN2CC=C3C(=C12)C=CC=C3)C(=O)N Chemical compound C1=CC(=CN2CC=C3C(=C12)C=CC=C3)C(=O)N BUQIAVHVUVAIHJ-UHFFFAOYSA-N 0.000 description 1
- QYXAJMMEEIYRMT-UHFFFAOYSA-N CCC(Cc(c1c2)cc(OCC(C)C)c2[O]=C)N(C=C2C(NC(C)COC)=O)C1=CC2=[U] Chemical compound CCC(Cc(c1c2)cc(OCC(C)C)c2[O]=C)N(C=C2C(NC(C)COC)=O)C1=CC2=[U] QYXAJMMEEIYRMT-UHFFFAOYSA-N 0.000 description 1
- AOLGBHQFLVIRJG-UHFFFAOYSA-O CCC(Cc(c1c2)cc(OCc3ccccc3)c2OC)N(C=C2C(N[S+](C)CC)=O)C1=CC2=O Chemical compound CCC(Cc(c1c2)cc(OCc3ccccc3)c2OC)N(C=C2C(N[S+](C)CC)=O)C1=CC2=O AOLGBHQFLVIRJG-UHFFFAOYSA-O 0.000 description 1
- OPXVTFDINCXCEE-UHFFFAOYSA-N CCC(Cc(cc1OCC2CC2)c2cc1OC)N(C=C1C(NC(C)COC)=O)C2=CC1=O Chemical compound CCC(Cc(cc1OCC2CC2)c2cc1OC)N(C=C1C(NC(C)COC)=O)C2=CC1=O OPXVTFDINCXCEE-UHFFFAOYSA-N 0.000 description 1
- SEVKBTNUUDEAMZ-UHFFFAOYSA-N COC1=CC2=C(C3=CC(C(=CN3CC2)C(=O)O)=O)C=C1OC Chemical compound COC1=CC2=C(C3=CC(C(=CN3CC2)C(=O)O)=O)C=C1OC SEVKBTNUUDEAMZ-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241001421711 Mithras Species 0.000 description 1
- YBXCZLLMINEZLK-UHFFFAOYSA-N N-[1-(4-methoxy-3-phenylmethoxyphenyl)butan-2-yl]formamide Chemical compound C(C1=CC=CC=C1)OC=1C=C(C=CC1OC)CC(CC)NC=O YBXCZLLMINEZLK-UHFFFAOYSA-N 0.000 description 1
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 108091006611 SLC10A1 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100021988 Sodium/bile acid cotransporter Human genes 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 229940124765 capsid inhibitor Drugs 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- IXTAVZYDEHSTCK-UHFFFAOYSA-N ethyl 10-methoxy-9-(3-methoxypropoxy)-2-oxo-6-propan-2-yl-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate Chemical compound COC=1C(=CC2=C(C3CC(C(=CN3C(C2)C(C)C)C(=O)OCC)=O)C1)OCCCOC IXTAVZYDEHSTCK-UHFFFAOYSA-N 0.000 description 1
- YNJCLVHQMKUPSZ-UHFFFAOYSA-N ethyl 10-methoxy-9-(3-methoxypropoxy)-2-oxo-6-propan-2-yl-6,7-dihydrobenzo[a]quinolizine-3-carboxylate Chemical compound COC=1C(=CC2=C(C3=CC(C(=CN3C(C2)C(C)C)C(=O)OCC)=O)C1)OCCCOC YNJCLVHQMKUPSZ-UHFFFAOYSA-N 0.000 description 1
- CATWLSDKIKBXQZ-UHFFFAOYSA-N ethyl 6-cyclobutyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate Chemical compound C1(CCC1)C1CC2=C(C3CC(C(=CN13)C(=O)OCC)=O)C=C(C(=C2)OCCCOC)OC CATWLSDKIKBXQZ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- VMVNZNXAVJHNDJ-UHFFFAOYSA-N methyl 2,2,2-trifluoroacetate Chemical compound COC(=O)C(F)(F)F VMVNZNXAVJHNDJ-UHFFFAOYSA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- CXQTTWVBUDFUNO-UHFFFAOYSA-N methyl piperidine-2-carboxylate Chemical compound COC(=O)C1CCCCN1 CXQTTWVBUDFUNO-UHFFFAOYSA-N 0.000 description 1
- BLWYXBNNBYXPPL-UHFFFAOYSA-N methyl pyrrolidine-2-carboxylate Chemical compound COC(=O)C1CCCN1 BLWYXBNNBYXPPL-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- FYCRNRZIEVLZDO-UHFFFAOYSA-N morpholin-4-ium-2-carboxylate Chemical compound OC(=O)C1CNCCO1 FYCRNRZIEVLZDO-UHFFFAOYSA-N 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004971 nitroalkyl group Chemical group 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- PQPFFKCJENSZKL-UHFFFAOYSA-N pentan-3-amine Chemical compound CCC(N)CC PQPFFKCJENSZKL-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-M prolinate Chemical compound [O-]C(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-M 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 description 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-M quinoline-3-carboxylate Chemical compound C1=CC=CC2=CC(C(=O)[O-])=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-M 0.000 description 1
- 150000003250 quinolizines Chemical class 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960005311 telbivudine Drugs 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
- C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- Y10S514/894—
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/077354 | 2014-05-13 | ||
| CN2014077354 | 2014-05-13 | ||
| CN2015074462 | 2015-03-18 | ||
| CNPCT/CN2015/074462 | 2015-03-18 | ||
| PCT/EP2015/060284 WO2015173164A1 (en) | 2014-05-13 | 2015-05-11 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160148715A true KR20160148715A (ko) | 2016-12-26 |
Family
ID=53055057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167034686A Ceased KR20160148715A (ko) | 2014-05-13 | 2015-05-11 | B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9920049B2 (https=) |
| EP (1) | EP3143020B1 (https=) |
| JP (1) | JP6568106B2 (https=) |
| KR (1) | KR20160148715A (https=) |
| CN (1) | CN106459032B (https=) |
| CA (1) | CA2948080A1 (https=) |
| MX (1) | MX2016014728A (https=) |
| RU (1) | RU2016146365A (https=) |
| WO (1) | WO2015173164A1 (https=) |
Families Citing this family (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122020020745B8 (pt) | 2010-07-22 | 2023-10-31 | Gilead Sciences Inc | Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende |
| RU2016146365A (ru) * | 2014-05-13 | 2018-06-19 | Ф. Хоффманн-Ля Рош Аг | Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| US9637485B2 (en) | 2014-11-03 | 2017-05-02 | Hoffmann-La Roche Inc. | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection |
| CN107207505B (zh) * | 2015-02-11 | 2018-12-14 | 豪夫迈·罗氏有限公司 | 治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物 |
| WO2016177655A1 (en) | 2015-05-04 | 2016-11-10 | F. Hoffmann-La Roche Ag | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2017016921A1 (en) * | 2015-07-24 | 2017-02-02 | F. Hoffmann-La Roche Ag | New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid |
| JP6506880B2 (ja) | 2015-07-27 | 2019-04-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体 |
| JP6559324B2 (ja) | 2015-07-28 | 2019-08-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染の治療及び予防用の新規６，７−ジヒドロピリド［２，１−ａ］フタラジン−２−オン類 |
| SI3349758T1 (sl) | 2015-09-16 | 2022-08-31 | Gilead Sciences, Inc. | Postopki za zdravljenje okužb z virusom arenaviridae |
| US20200270265A1 (en) | 2016-02-19 | 2020-08-27 | Novartis Ag | Tetracyclic pyridone compounds as antivirals |
| JP6904970B2 (ja) | 2016-03-07 | 2021-07-21 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| CN109414508A (zh) | 2016-05-27 | 2019-03-01 | 吉利德科学公司 | 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法 |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| CN109843296A (zh) | 2016-06-10 | 2019-06-04 | 英安塔制药有限公司 | 乙型肝炎抗病毒药剂 |
| WO2017216685A1 (en) | 2016-06-16 | 2017-12-21 | Novartis Ag | Pentacyclic pyridone compounds as antivirals |
| WO2017216686A1 (en) | 2016-06-16 | 2017-12-21 | Novartis Ag | 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals |
| CN109414448B (zh) * | 2016-06-17 | 2021-10-26 | 豪夫迈·罗氏有限公司 | 用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子 |
| CN109415368B (zh) * | 2016-07-14 | 2021-04-30 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的羧基6,7-二氢-4H-吡唑并[1,5-a]吡嗪化合物 |
| CN107759585A (zh) * | 2016-07-29 | 2018-03-06 | 银杏树药业(苏州)有限公司 | 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用 |
| CN110156774A (zh) | 2016-07-29 | 2019-08-23 | 新波制药有限公司 | 用于治疗hbv感染的新颖治疗剂 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018041873A1 (en) * | 2016-09-01 | 2018-03-08 | F. Hoffmann-La Roche Ag | Process for the preparation of (6s)-6-isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid |
| CN109923106B (zh) | 2016-09-02 | 2022-09-13 | 吉利德科学公司 | toll样受体调节剂化合物 |
| EP3507288B1 (en) | 2016-09-02 | 2020-08-26 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| TW201811788A (zh) | 2016-09-09 | 2018-04-01 | 瑞士商諾華公司 | 作為抗病毒劑之多環吡啶酮化合物 |
| IL265921B2 (en) | 2016-10-14 | 2024-05-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| WO2018073753A1 (en) | 2016-10-18 | 2018-04-26 | Novartis Ag | Fused tetracyclic pyridone compounds as antivirals |
| US11124495B2 (en) | 2016-11-03 | 2021-09-21 | Hoffmann-La Roche, Inc. | Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection |
| CN110088103B (zh) | 2016-11-03 | 2022-04-12 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的新的四氢吡啶并嘧啶化合物 |
| CN110088104B (zh) | 2016-11-03 | 2022-04-12 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的四氢吡啶并嘧啶化合物 |
| TWI794190B (zh) * | 2016-11-07 | 2023-03-01 | 加拿大商愛彼特生物製藥公司 | 含有取代的吡啶酮之三環化合物及其使用方法 |
| WO2018087345A1 (en) | 2016-11-14 | 2018-05-17 | F. Hoffmann-La Roche Ag | COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON |
| CN106810548B (zh) * | 2017-01-13 | 2019-02-15 | 苏州爱科百发生物医药技术有限公司 | 一种二氢异喹啉类化合物 |
| TWI820984B (zh) | 2017-01-31 | 2023-11-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| UY37581A (es) | 2017-02-02 | 2018-08-31 | Gilead Sciences Inc | Compuestos para el tratamiento de la infección por virus de la hepatitis b |
| DK3587420T3 (da) * | 2017-02-23 | 2021-06-07 | Fujian Cosunter Pharmaceutical Co Ltd | Tricyklisk forbindelse og anvendelser heraf |
| US10682368B2 (en) | 2017-03-14 | 2020-06-16 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| AU2018238138A1 (en) | 2017-03-21 | 2019-10-17 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| AR111419A1 (es) * | 2017-04-27 | 2019-07-10 | Novartis Ag | Compuestos fusionados de indazol piridona como antivirales |
| AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| CN108530449B (zh) * | 2017-05-22 | 2021-05-07 | 河南春风医药科技有限公司 | 用于治疗或预防乙型肝炎病毒感染的化合物及其制备方法与应用 |
| CN110066278B (zh) * | 2017-06-01 | 2021-06-08 | 广东东阳光药业有限公司 | 稠合三环类化合物及其在药物中的应用 |
| WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS |
| US10952978B2 (en) | 2017-08-28 | 2021-03-23 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| SI3692040T1 (sl) * | 2017-10-05 | 2023-05-31 | Glaxosmithkline Intellectual Property Development Limited | Kemijske spojine |
| UA126931C2 (uk) | 2017-10-16 | 2023-02-22 | Ф. Хоффманн-Ля Рош Аг | МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B |
| US12171755B2 (en) | 2017-10-25 | 2024-12-24 | Children's Medical Center Corporation | PAPD5 inhibitors and methods of use thereof |
| EP3710455A1 (en) | 2017-11-17 | 2020-09-23 | Novartis AG | Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b |
| TW201927789A (zh) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| TW201936192A (zh) | 2017-12-06 | 2019-09-16 | 美商因那塔製藥公司 | B 型肝炎抗病毒試劑 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| JP2021507906A (ja) * | 2017-12-20 | 2021-02-25 | ノバルティス アーゲー | 抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物 |
| TW201930276A (zh) * | 2017-12-22 | 2019-08-01 | 德商拜耳廠股份有限公司 | 羥基異㗁唑啉及其衍生物 |
| EA038176B9 (ru) * | 2018-01-04 | 2021-09-07 | Фуцзянь Косантер Фармасьютикал Ко., Лтд. | Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
| CN111801331A (zh) | 2018-02-28 | 2020-10-20 | 诺华股份有限公司 | 吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途 |
| US11702427B2 (en) | 2018-03-12 | 2023-07-18 | Arbutus Biopharma Corporation | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| AU2019252441A1 (en) | 2018-04-12 | 2020-10-22 | Arbutus Biopharma Corporation | Methods for preparing substituted pyridinone-containing tricyclic compounds |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| SG11202012759XA (en) | 2018-07-03 | 2021-01-28 | Hoffmann La Roche | Oligonucleotides for modulating tau expression |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TWI869058B (zh) | 2018-07-27 | 2025-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN110862390B (zh) | 2018-08-28 | 2023-05-09 | 广东东阳光药业有限公司 | 稠合三环类化合物及其在药物中的应用 |
| UY38383A (es) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| CA3111046A1 (en) | 2018-09-30 | 2020-04-02 | Sunshine Lake Pharma Co., Ltd. | Fused tetracyclic compounds and uses thereof in medicine |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| TW202415643A (zh) | 2018-12-12 | 2024-04-16 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| CN114014854B (zh) * | 2019-01-08 | 2023-04-07 | 苏州爱科百发生物医药技术有限公司 | 一种二氢异喹啉类化合物 |
| EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| KR102707808B1 (ko) | 2019-03-07 | 2024-09-19 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US12486234B2 (en) | 2019-04-24 | 2025-12-02 | Children's Medical Center Corporation | PAPD5 inhibitors and methods of use thereof |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CN119770638A (zh) | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| US11660307B2 (en) | 2020-01-27 | 2023-05-30 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| JP7554841B2 (ja) | 2020-03-12 | 2024-09-20 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノヌクレオシドを調製する方法 |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| US12569500B2 (en) | 2020-05-15 | 2026-03-10 | Fujian Akeylink Biotechnology Co., Ltd. | Combination comprising tricycle compound and use thereof in preparation of medicament for treating HBV |
| CA3179226A1 (en) | 2020-05-29 | 2021-12-02 | Tomas Cihlar | Remdesivir treatment methods |
| AU2021296841B2 (en) | 2020-06-24 | 2025-01-23 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| PE20230779A1 (es) | 2020-08-07 | 2023-05-09 | Gilead Sciences Inc | Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico |
| CN111943946B (zh) * | 2020-08-19 | 2022-07-01 | 中国医学科学院医药生物技术研究所 | 含有氮杂环片段的二氢喹嗪酮羧酸类化合物及其应用 |
| AU2021330835B2 (en) | 2020-08-24 | 2023-12-14 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
| SI4204421T1 (sl) | 2020-08-27 | 2024-07-31 | Gilead Sciences, Inc., | Spojine in postopki za zdravljenje virusnih okužb |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| EP4346772B1 (en) | 2021-05-26 | 2026-04-01 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| IL315102A (en) | 2022-03-02 | 2024-10-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| KR20240154646A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| PE20250419A1 (es) | 2022-03-03 | 2025-02-14 | Gilead Sciences Inc | Compuestos antivirales y metodos de elaboracion y uso de los mismos |
| JP2025508941A (ja) | 2022-03-03 | 2025-04-10 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルス化合物並びにその作製及び使用方法 |
| JP2025519390A (ja) | 2022-06-06 | 2025-06-26 | ギリアード サイエンシーズ， インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２を含むウイルス感染の治療方法 |
| WO2024006376A1 (en) | 2022-06-29 | 2024-01-04 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| EP4547665A1 (en) | 2022-06-30 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| WO2024173458A1 (en) | 2023-02-16 | 2024-08-22 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| IL326322A (en) | 2023-08-31 | 2026-04-01 | Gilead Sciences Inc | Antiviral compounds and methods for their production and use |
| US20250090537A1 (en) | 2023-08-31 | 2025-03-20 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| US20250099476A1 (en) | 2023-09-06 | 2025-03-27 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US20250109157A1 (en) | 2023-09-28 | 2025-04-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60197684A (ja) * | 1984-03-21 | 1985-10-07 | Dainippon Pharmaceut Co Ltd | ベンゾ〔ａ〕キノリジン誘導体およびその塩 |
| EA201691261A1 (ru) * | 2014-01-30 | 2016-11-30 | Ф. Хоффманн-Ля Рош Аг | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b |
| RU2016146365A (ru) * | 2014-05-13 | 2018-06-19 | Ф. Хоффманн-Ля Рош Аг | Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b |
| US9637485B2 (en) * | 2014-11-03 | 2017-05-02 | Hoffmann-La Roche Inc. | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection |
-
2015
- 2015-05-11 RU RU2016146365A patent/RU2016146365A/ru unknown
- 2015-05-11 JP JP2016567506A patent/JP6568106B2/ja active Active
- 2015-05-11 KR KR1020167034686A patent/KR20160148715A/ko not_active Ceased
- 2015-05-11 CN CN201580024679.0A patent/CN106459032B/zh active Active
- 2015-05-11 EP EP15721009.7A patent/EP3143020B1/en active Active
- 2015-05-11 CA CA2948080A patent/CA2948080A1/en not_active Abandoned
- 2015-05-11 WO PCT/EP2015/060284 patent/WO2015173164A1/en not_active Ceased
- 2015-05-11 MX MX2016014728A patent/MX2016014728A/es unknown
-
2016
- 2016-11-11 US US15/349,343 patent/US9920049B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016014728A (es) | 2017-03-23 |
| CN106459032A (zh) | 2017-02-22 |
| WO2015173164A1 (en) | 2015-11-19 |
| US20170057952A1 (en) | 2017-03-02 |
| EP3143020A1 (en) | 2017-03-22 |
| US9920049B2 (en) | 2018-03-20 |
| CA2948080A1 (en) | 2015-11-19 |
| CN106459032B (zh) | 2019-04-05 |
| JP6568106B2 (ja) | 2019-08-28 |
| RU2016146365A3 (https=) | 2018-06-19 |
| RU2016146365A (ru) | 2018-06-19 |
| EP3143020B1 (en) | 2019-08-21 |
| JP2017515844A (ja) | 2017-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6568106B2 (ja) | Ｂ型肝炎ウイルス感染症の治療及び予防のための新規ジヒドロキノリジノン類 | |
| US10336751B2 (en) | Tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | |
| US10093671B2 (en) | 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | |
| US10053461B2 (en) | Tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | |
| US10150740B2 (en) | 6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection | |
| JP6420491B2 (ja) | Ｂ型肝炎ウイルス感染の治療又は予防用の新規６，７−ジヒドロベンゾ［ａ］キノリジン−２−オン誘導体 | |
| JP2017504633A (ja) | Ｂ型肝炎ウイルス感染の治療及び予防のための新規なジヒドロキノリジノン | |
| HK1233622A1 (en) | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | |
| HK1233622B (zh) | 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类 | |
| KR20160097371A (ko) | B형 간염 바이러스 감염의 치료 및 예방을 위한 다이하이드로퀴놀리진온 | |
| HK1251221B (zh) | 用於治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20161212 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20161212 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20180320 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20180831 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20180320 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |